STOCK TITAN

Artivion Reports First Quarter 2023 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
earnings

First Quarter and Recent Business Highlights:

  • Achieved revenue of $83.2 million in the first quarter of 2023 versus $77.2 million in the first quarter of 2022, an increase of 8% on a GAAP basis and an increase of 10% on a non-GAAP constant currency basis
  • On-X revenues increased 23% on a GAAP basis and 24% on a non-GAAP constant currency basis in the first quarter of 2023 compared to the first quarter of 2022
  • Aortic stent graft revenues increased 3% on a GAAP basis and 8% on a non-GAAP constant currency basis in the first quarter of 2023 compared to the first quarter of 2022
  • Received notice from the FDA that the PerClot PMA is approvable subject to finalization of the Establishment Inspection Report (EIR) for our recent pre-approval inspection

ATLANTA, May 4, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the first quarter ended March 31, 2023.

"I am pleased with our first quarter results, as we delivered constant currency revenue growth of 10% year-over-year and remain on track to achieve or exceed the revenue and EBITDA growth targets for 2023 and beyond that we outlined last year. Our strong performance was driven by year-over-year On-X revenue growth of 24% and aortic stent graft revenue growth of 8%, with BioGlue also growing 8%, and tissue processing revenue growing 7%, all on a constant currency basis. We also saw Asia Pacific and Latin American revenue grow 18% and 34%, respectively, on a constant currency basis compared to last year," said Pat Mackin, Chairman, President, and Chief Executive Officer.

Mr. Mackin added, "In addition to our strong financial performance, we recently received an Approvable Letter from the FDA for the PerClot PMA and expect approval after the report for our recent pre-approval inspection is finalized. Following this approval, we will receive a $14.3 million dollar milestone payment, net of amounts owed to our former partner, and begin shipping revenue generating PerClot product to Baxter. Meanwhile, our recent hires at our German manufacturing facility continue to ramp up their productivity, better positioning the Company to meet the robust demand for our stent grafts. We are also pleased to report that patient enrollment for the PERSEVERE trial evaluating AMDS, a simple, elegant stent graft solution to treat aortic arch disease, remains on track. Finally, we remain confident in our ability to grow our total addressable market by developing our pipeline and expanding our presence into new markets and within our existing markets."

Mr. Mackin concluded, "We believe we remain well on track to meet our 2024 year-end commitments to deliver double-digit compounded annual constant currency revenue growth and achieve adjusted EBITDA in excess of $75.0 million."

First Quarter 2023 Financial Results
Total revenues for the first quarter of 2023 were $83.2 million, an increase of 8% on a GAAP basis and an increase of 10% on a non-GAAP constant currency basis, both compared to the first quarter of 2022.

Net loss for the first quarter of 2023 was ($13.5) million, or ($0.33) per fully diluted common share, compared to net loss of ($3.4) million, or ($0.08) per fully diluted common share for the first quarter of 2022. Net loss for the first quarter of 2023 includes a pretax charge of $4.8 million related to contingent consideration for the acquisition of AMDS. Non-GAAP net income for the first quarter of 2023 was $769,000, or $0.02 per fully diluted common share, compared to non-GAAP net income of $1.1 million, or $0.03 per fully diluted common share for the first quarter of 2022. 

2023 Financial Outlook
Artivion is raising its revenue guidance range and now expects constant currency revenue growth of between 9% and 12%, compared to the previous range of between 8% and 12%, for the full year 2023 compared to 2022. The Company expects revenues to be in a range of between $337.0 million and $348.0 million, compared to the previous range of between $331.0 million and $343.0 million.

Additionally, Artivion expects adjusted EBITDA, as reported, to increase greater than 25% in 2023 compared to 2022, resulting in adjusted EBITDA in excess of $52.0 million in 2023, compared to its previous guidance of adjusted EBITDA in excess of $50.0 million.

The Company's financial performance for 2023 and future periods is subject to the risks identified below.

Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, including non-GAAP revenue, non-GAAP net income, non-GAAP EBITDA, and non-GAAP general, administrative, and marketing expenses. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with US GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company's non-GAAP revenues are adjusted for the impact of changes in currency exchange. The Company's non-GAAP net income; non-GAAP EBITDA; and non-GAAP general, administrative, and marketing results exclude (as applicable) depreciation and amortization expense; interest income and expense; stock-based compensation expense; loss or gain on foreign currency revaluation; clinical trial termination expense; income tax expense or benefit; corporate rebranding expense; business development, integration, and severance income or expense; non-cash interest expense; and gain from sale of non-financial assets. The Company generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Company management believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions; the operating expense structure of the Company's existing and recently acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses, and the transaction and integration expenses incurred in connection with recently acquired and divested product lines; and the operating expense structure excluding fluctuations resulting from foreign currency revaluation and stock-based compensation expense. The Company believes it is useful to exclude certain expenses because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as impact of recent acquisitions, non-cash expense related to amortization of previously acquired tangible and intangible assets, and any related adjustments to their carrying values. The Company has adjusted for the impact of changes in currency exchange from certain revenues to evaluate comparable product growth rates on a constant currency basis. The Company does, however, expect to incur similar types of expenses and currency exchange impacts in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur. Company management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety, including the reconciliation of GAAP to non-GAAP financial measures."

Webcast and Conference Call Information
The Company will hold a teleconference call and live webcast later today, May 4, 2023, at 4:30 p.m. ET to discuss the results, followed by a question and answer session. To participate in the conference call dial 862-298-0702 a few minutes prior to 4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13737780.

The live webcast and replay can be accessed by going to the Investors section of the Artivion website at www.Artivion.com and selecting the heading Webcasts & Presentations.

About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.

Forward Looking Statements
Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs that we will be better positioned to meet the robust demand for our stent grafts by the enhanced productivity of our larger German production staff; we remain confident in our ability to grow our total addressable market by developing our pipeline and expanding our presence into new markets and within our existing markets; and we remain well on track to meet our 2024 year-end commitments to deliver double-digit compounded annual constant currency revenue growth and achieve adjusted EBITDA in excess of $75.0 million." These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations, including that the benefits anticipated from the Ascyrus Medical LLC transaction and Endospan agreements may not be achieved at all or at the levels we had originally anticipated; the benefits anticipated from our clinical trials may not be achieved or achieved on our anticipated timeline; our products may not be able to consistently retain their existing regulatory approvals or special regulatory approvals in order to be commercialized; products in our pipeline may not receive regulatory approval at all or receive regulatory approval on our anticipated timelines; our products that obtain regulatory approval may not be adopted by the market as much as we anticipate or at all; and the continued effects of pandemics, including COVID-19 and new COVID-19 variants, and continued hospital staffing shortages could adversely impact our results. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2022 and our Form 10-Q for the quarter ended March 31, 2023. Artivion does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.

 

Artivion, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Loss
In Thousands, Except Per Share Data
(Unaudited)



Three Months Ended
March 31,


2023


2022

Revenues:




Products

$           62,291


$           57,542

Preservation services

20,938


19,671

Total revenues

83,229


77,213





Cost of products and preservation services:




Products

19,533


17,408

Preservation services

9,969


9,086

Total cost of products and preservation services

29,502


26,494





Gross margin

53,727


50,719





Operating expenses:




General, administrative, and marketing

50,365


38,955

Research and development

7,223


10,128

Total operating expenses

57,588


49,083





Operating (loss) income

(3,861)


1,636





Interest expense

6,096


3,948

Interest income

(75)


(16)

Other (income) expense, net

(963)


133





Loss before income taxes

(8,919)


(2,429)

Income tax expense

4,613


960





Net loss

$          (13,532)


$            (3,389)





Loss per share:




Basic

$              (0.33)


$              (0.08)

Diluted

$              (0.33)


$              (0.08)





Weighted-average common shares outstanding:




Basic

40,432


39,850

Diluted

40,432


39,850





Net loss

$          (13,532)


$            (3,389)

Other comprehensive loss:




Foreign currency translation adjustments

3,616


(3,775)

Comprehensive loss

$            (9,916)


$            (7,164)

 

Artivion, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
In Thousands  







March 31,
2023


December 31,
2022


(Unaudited)



ASSETS




Current assets:




Cash and cash equivalents

$             30,773


$             39,351

Trade receivables, net

62,760


61,820

Other receivables

3,952


7,764

Inventories, net

76,273


74,478

Deferred preservation costs, net

47,415


46,371

Prepaid expenses and other

19,508


17,550

Total current assets

240,681


247,334





Goodwill

245,648


243,631

Acquired technology, net

149,833


151,263

Operating lease right-of-use assets, net

41,473


41,859

Property and equipment, net

38,716


38,674

Other intangibles, net

30,807


31,384

Deferred income taxes

2,373


1,314

Other assets

7,542


7,339

Total assets

$           757,073


$           762,798





LIABILITIES AND SHAREHOLDERS' EQUITY




Current liabilities:




Accounts payable

$               9,473


$             12,004

Accrued expenses

9,678


12,374

Accrued compensation

9,028


13,810

Taxes payable

6,911


2,635

Current maturities of operating leases

3,398


3,308

Accrued procurement fees

2,155


2,111

Current portion of long-term debt

1,620


1,608

Other liabilities

1,698


1,825

Total current liabilities

43,961


49,675





Long-term debt

306,279


306,499

Contingent consideration

45,200


40,400

Non-current maturities of operating leases

40,774


41,257

Deferred income taxes

23,826


24,499

Deferred compensation liability

6,127


5,468

Non-current finance lease obligation

3,582


3,644

Other liabilities

7,407


7,027

Total liabilities

$           477,156


$           478,469





Commitments and contingencies








Shareholders' equity:




Preferred stock


Common stock (75,000 shares authorized, 42,366 and 41,830 shares issued and outstanding in
2023 and 2022, respectively)

424


418

Additional paid-in capital

342,883


337,385

Retained deficit

(30,749)


(17,217)

Accumulated other comprehensive loss

(17,993)


(21,609)

Treasury stock, at cost, 1,487 shares as of March 31, 2023 ‎and December 31, 2022

(14,648)


(14,648)

Total shareholders' equity

279,917


284,329





Total liabilities and shareholders' equity

$           757,073


$           762,798

 

Artivion, Inc. and Subsidiaries
Condensed Consolidated Statement of Cash Flows
In Thousands
(Unaudited)



Three Months Ended
March 31,


2023


2022

Net cash flows from operating activities:




Net loss

$          (13,532)


$            (3,389)





Adjustments to reconcile net loss to net cash from operating activities:




Depreciation and amortization

5,734


5,881

Change in fair value of contingent consideration

4,800


(1,800)

Non-cash compensation

3,341


3,166

Non-cash lease expense

1,802


1,920

Write-down of inventories and deferred preservation costs

1,123


989

Deferred income taxes

(2,167)


(2,966)

Other

754


496

Changes in operating assets and liabilities:




Receivables

3,540


(1,710)

Prepaid expenses and other assets

(2,014)


1,494

Inventories and deferred preservation costs

(3,222)


(1,359)

Accounts payable, accrued expenses, and other liabilities

(6,313)


(3,320)

Net cash flows used in operating activities

(6,154)


(598)





Net cash flows from investing activities:




Capital expenditures

(2,238)


(2,239)

Acquisition of intangible assets

(605)


(469)

Net cash flows used in investing activities

(2,843)


(2,708)





Net cash flows from financing activities:




Proceeds from exercise of stock options and issuance of common stock

2,581


2,318

Redemption and repurchase of stock to cover tax withholdings

(590)


(1,730)

Repayment of term loan

(690)


(694)

Other

(130)


(129)

Net cash flows provided by (used in) financing activities

1,171


(235)





Effect of exchange rate changes on cash and cash equivalents

(752)


(61)

Decrease in cash and cash equivalents

(8,578)


(3,602)





Cash and cash equivalents beginning of period

39,351


55,010

Cash and cash equivalents end of period

$           30,773


$           51,408

 

Artivion, Inc. and Subsidiaries
Financial Highlights
In Thousands
(Unaudited)



Three Months Ended
March 31,


2023


2022

Products:




Aortic stent grafts

$             26,150


$             25,506

On-X

17,656


14,371

Surgical sealants

16,703


15,681

Other

1,782


1,984

Total products

62,291


57,542





Preservation services

20,938


19,671

Total revenues

$             83,229


$             77,213





Revenues:




US

$             41,333


$             37,735

    International

41,896


39,478

Total revenues

$             83,229


$             77,213

 

Artivion, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP
Revenues and General, Administrative, and Marketing Expense
In Thousands 
(Unaudited)



Revenues for the
Three Months Ended
March 31,


Percent
Change
From Prior
Year


2023


2022



US GAAP


US GAAP


Exchange
rate effect


Constant
Currency


Constant
Currency

Products:










Aortic stent grafts

$            26,150


$            25,506


$           (1,238)


$            24,268


8 %

On-X

17,656


14,371


(146)


14,225


24 %

Surgical sealants

16,703


15,681


(286)


15,395


8 %

Other

1,782


1,984


(15)


1,969


-9 %

Total products

62,291


57,542


(1,685)


55,857


12 %











Preservation services

20,938


19,671


(35)


19,636


7 %

Total

$            83,229


$            77,213


$           (1,720)


$            75,493


10 %

 


Three Months Ended
March 31,


2023


2022

Reconciliation of G&A expense, GAAP to adjusted G&A, non-GAAP:




General, administrative, and marketing expense, GAAP

$            50,365


$            38,955

  Business development, integration, and severance expense (income)

4,997


(1,579)

  Corporate rebranding expense

149


883

Adjusted G&A, non-GAAP

$            45,219


$            39,651

 

Artivion, Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP
Adjusted EBITDA
In Thousands
(Unaudited)



Three Months Ended
March 31,


2023


2022

Reconciliation of net loss, GAAP to adjusted EBITDA, non-GAAP:




Net loss, GAAP

$        (13,532)


$          (3,389)

Adjustments:




Interest expense

6,096


3,948

Depreciation and amortization expense

5,734


5,881

  Business development, integration, and severance expense (income)

5,452


(1,579)

Income tax expense

4,613


960

Stock-based compensation expense

3,341


3,166

Corporate rebranding expense

149


883

Interest income

(75)


(16)

(Gain) loss on foreign currency revaluation

(973)


133

Adjusted EBITDA, non-GAAP

$         10,805


$            9,987

 

Artivion Inc. and Subsidiaries
Reconciliation of GAAP to Non-GAAP
Net Income and Diluted Income Per Common Share
In Thousands, Except Per Share Data
(Unaudited)



Three Months Ended
March 31,


2023


2022

GAAP:




Loss before income taxes

$             (8,919)


$             (2,429)

Income tax expense

4,613


960

Net loss

$           (13,532)


$             (3,389)





Diluted loss per common share

$               (0.33)


$               (0.08)





Diluted weighted-average common shares outstanding

40,432


39,850





Reconciliation of loss before income taxes, GAAP to adjusted income, non-GAAP:




Loss before income taxes, GAAP:

$             (8,919)


$             (2,429)

Adjustments:




Business development, integration, and severance expense (income)

5,452


(1,579)

Amortization expense

3,881


4,084

Non-cash interest expense

462


456

Corporate rebranding expense

149


883

Adjusted income before income taxes, non-GAAP

1,025


1,415





Income tax expense calculated at a tax rate of 25%

256


354

Adjusted net income, non-GAAP

$                  769


$               1,061





Reconciliation of diluted loss per common share, GAAP to adjusted diluted income per
      common share, non-GAAP:




Diluted loss per common share, GAAP:

$               (0.33)


$               (0.08)

Adjustments:




Effect of 25% tax rate

0.17


0.04

Business development, integration, and severance expense (income)

0.13


(0.04)

Amortization expense

0.10


0.10

Non-cash interest expense

0.01


0.01

Corporate rebranding expense


0.02

Tax effect of non-GAAP adjustments

(0.06)


(0.02)

Adjusted diluted income per common share, non-GAAP

$                 0.02


$                 0.03





Reconciliation of diluted weighted-average common shares outstanding GAAP to diluted
      weighted-average common shares outstanding, non-GAAP:




Diluted weighted-average common shares outstanding, GAAP:

40,432


39,850

Adjustments:




Effect of dilutive stock options and awards

418


441

Diluted weighted-average common shares outstanding, non-GAAP

40,850


40,291

 

Contacts:

Artivion

Gilmartin Group LLC

D. Ashley Lee

Brian Johnston / Lynn Lewis

Executive Vice President &

Phone:  332-895-3222

Chief Financial Officer

investors@artivion.com

Phone: 770-419-3355


 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-reports-first-quarter-2023-financial-results-301816441.html

SOURCE Artivion, Inc.

Artivion Inc

NYSE:AORT

AORT Rankings

AORT Latest News

AORT Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Kennesaw

About AORT

cryolife, headquartered in georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. cryolife using its proprietary synergraft® technology processes the cryovalve® sg pulmonary heart valve and cryopatch® sg pulmonary cardiac patch. cryolife’s bioglue® surgical adhesive is approved in the u.s. for use as an adjunct to sutures and staples to help control bleeding, ce marked in the european community, approved in canada and australia for use in soft tissue repair, and in japan for use in the repair of aortic dissections. cryolife’s cardiogenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as transmyocardial revascularization (tmr). cryolife markets the hero® graft, which provides vascular access for hemodialysis patients. cryolife distributes perclot®, an absorbable powdered hemostat, in international markets. cryolife’s biofoam® surgica